Small team, high potential ResistanceBio is a very small company (2-10 employees) in pharmaceutical manufacturing focused on treatment-resistant cancer, suggesting agility and a potential need for scalable, outsourced or co-development relationships, CRO/CMO partnerships, and targeted pilot collaborations.

Early-stage funding With total funding around $25M and a recent $12.8M venture round in January 2024, they may be actively seeking strategic investors, grant opportunities, and non-dilutive funding options, as well as partnerships that accelerate clinical pre-clinical to early development timelines.

Clinically relevant focus Their emphasis on overcoming clinical treatment resistance implies potential sales opportunities for platforms and services in biomarker discovery, resistance mechanism analysis, companion diagnostics, and precision oncology tools that enable trial stratification and new therapeutic strategies.

Technology footprint Utilizing cloud and engineering tools (AWS, Python, SOLIDWORKS, Webflow, WordPress) indicates readiness for digital infrastructure, data analytics, and product visualization collaborations; explore partnerships for data management, computational biology, and digital marketing support.

Market positioning Compared with larger peers, resistanceBio sits in a niche with modest revenue but potential for rapid growth via strategic collaborations with mid-size biotech firms and contract services; identify co-development, licensing, and milestone-driven deals to align with their funding trajectory.